Abstract: FR-PO1169
Kidney Screening in Northern Mexico: Confronting Silent CKD
Session Information
- CKD: Screening, Diagnosis, Serum and Urine Biomarkers, and Scoring Indices
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Rodríguez Ibarra, Kenya Y, Hospital Universitario Dr. José Eleuterio González, Monterrey, Nuevo León, Mexico
- Borbolla-Flores, Paola, Hospital Universitario Dr. José Eleuterio González, Monterrey, Nuevo León, Mexico
- Gomez Villarreal, Juan Pablo, Hospital Universitario Dr. José Eleuterio González, Monterrey, Nuevo León, Mexico
- Olivo, Mara Cecilia, Hospital Universitario Dr. José Eleuterio González, Monterrey, Nuevo León, Mexico
- Aroca Martinez, Gustavo, Universidad Simon Bolivar Centro de Investigaciones en Ciencias de la Vida, Barranquilla, Atlántico, Colombia
- Villavicencio, Vanessa, Pontificia Universidad Catolica Argentina, Buenos Aires, Argentina
- Rizo Topete, Lilia Maria, Hospital Universitario Dr. José Eleuterio González, Monterrey, Nuevo León, Mexico
Background
Chronic Kidney Disease (CKD) is a growing public health problem in Mexico. Preventive approaches such as Point Of Care (POC) testing represent a valuable option to improve early detection and prevent CKD progression, especially in vulnerable populations with limited access to healthcare services.
Methods
International, multicenter, cross-sectional study including adults from vulnerable populations. Recruitment takes place at the “Dr. José Eleuterio González” Hospital Universitario (March and May 2025). Data collection includes CKD screening through a digital risk factor survey, anthropometric measurements, urine protein testing via dipstick, and creatinine and eGFR measurements using the Nova Max Pro POC device.
Results
170 patients participated; 28.2% (48) were male. CKD markers were detected in 50 (29.41%), defined by eGFR <60 (20.7%, 35) or proteinuria (14.71%, 25) (Fig.1). Median of creatinine was 1.12 mg/dL (± 0.69) and eGRFR 73.0 ml/min/1.73 m2 (± 18.2). HTN (28.24%, 48) and DT2 (25.88%, 44) were common.
Patients with CKD were older (p = 0.006), had higher systolic BP (p = 0.0272), heart rate (p = 0.0486), and creatinine (p < 0.001), and lower eGFR (p < 0.001).
CKD was significantly associated with HTN (p = 0.0005), DT2 (p = 0.0037), use of antidiabetics (p = 0.0042), antihypertensives (p = 0.0219), lipid-lowering drugs (p = 0.019), and history of proteinuria or hematuria (p = 0.0366). Educational level also correlated with CKD stage (p = 0.0375).
Conclusion
The high prevalence of CKD markers highlights the urgent need to implement systematic screening programs. POC testing and dipstick proteinuria are effective tools for early detection, allowing timely interventions that prevent progression and improve population renal health. These strategies should be integrated into primary care to reduce the prevalence of CKD in vulnerable communities.
Funding
- Clinical Revenue Support